Our biotechnology company developing therapies based on cellular mechanisms identified by a world-renowned research group
Our collaborators and partners are driven by a desire to contribute to the development of new ways of fighting cancer
Concept and link to cancer
Dependence Receptors are trans-membrane proteins that receive signals and transmit them inside cells. They play a key role in the control of tumor development and can be considered as tumor suppressors.
Therapeutic strategy
Based on the concept of Dependance Receptors, the therapeutic strategy of NETRIS Pharma is to block the interaction between DRs and their ligands to restore the tumor suppressing functions.
Research
NETRIS Pharma identifies the modifications of Dependance Receptors in cancer, perform proof of concept studies and develop monoclonal antibodies as drug candidates.
Located in Léon Bérard Cancer Center (Lyon, France),
NETRIS Pharma is a unique model of a biotechnology company
integrated within a comprehensive cancer center
